Johannes Häberle1, Martina Huemer. 1. Division of Metabolism, University Children's Hospital Zurich, 8032, Zürich, Switzerland, Johannes.Haeberle@kispi.uzh.ch.
Abstract
BACKGROUND: Implementation of guidelines and assessment of their adaptation is not an extensively investigated process in the field of rare diseases. However, whether targeted recipients are reached and willing and able to follow the recommendations has significant impact on the efficacy of guidelines. In 2012, a guideline for the management of urea cycle disorders (UCDs) has been published. We evaluate the efficacy of implementation, adaptation, and use of the UCD guidelines by applying different strategies. METHODS: (i) Download statistics from online sources were recorded. (ii) Facilities relevant for the implementation of the guidelines were assessed in pediatric units in Germany and Austria. (iii) The guidelines were evaluated by targeted recipients using the AGREE instrument. (iv) A regional networking-based implementation process was evaluated. RESULTS: (i) Download statistics revealed high access with an increase in downloads over time. (ii) In 18% of hospitals ammonia testing was not available 24/7, and emergency drugs were often not available. (iii) Recipient criticism expressed in the AGREE instrument focused on incomplete inclusion of patients' perspectives. (iv) The implementation process improved the availability of ammonia measurements and access to emergency medication, patient care processes, and cooperation between nonspecialists and specialists. CONCLUSION: Interest in the UCD guidelines is high and sustained, but more precise targeting of the guidelines is advisable. Surprisingly, many hospitals do not possess all facilities necessary to apply the guidelines. Regional network and awareness campaigns result in the improvement of both facilities and knowledge.
BACKGROUND: Implementation of guidelines and assessment of their adaptation is not an extensively investigated process in the field of rare diseases. However, whether targeted recipients are reached and willing and able to follow the recommendations has significant impact on the efficacy of guidelines. In 2012, a guideline for the management of urea cycle disorders (UCDs) has been published. We evaluate the efficacy of implementation, adaptation, and use of the UCD guidelines by applying different strategies. METHODS: (i) Download statistics from online sources were recorded. (ii) Facilities relevant for the implementation of the guidelines were assessed in pediatric units in Germany and Austria. (iii) The guidelines were evaluated by targeted recipients using the AGREE instrument. (iv) A regional networking-based implementation process was evaluated. RESULTS: (i) Download statistics revealed high access with an increase in downloads over time. (ii) In 18% of hospitals ammonia testing was not available 24/7, and emergency drugs were often not available. (iii) Recipient criticism expressed in the AGREE instrument focused on incomplete inclusion of patients' perspectives. (iv) The implementation process improved the availability of ammonia measurements and access to emergency medication, patient care processes, and cooperation between nonspecialists and specialists. CONCLUSION: Interest in the UCD guidelines is high and sustained, but more precise targeting of the guidelines is advisable. Surprisingly, many hospitals do not possess all facilities necessary to apply the guidelines. Regional network and awareness campaigns result in the improvement of both facilities and knowledge.
Authors: P A Gross; S Greenfield; S Cretin; J Ferguson; J Grimshaw; R Grol; N Klazinga; W Lorenz; G S Meyer; C Riccobono; S C Schoenbaum; P Schyve; C Shaw Journal: Med Care Date: 2001-08 Impact factor: 2.983
Authors: Jana Heringer; S P Nikolas Boy; Regina Ensenauer; Birgit Assmann; Johannes Zschocke; Inga Harting; Thomas Lücke; Esther M Maier; Chris Mühlhausen; Gisela Haege; Georg F Hoffmann; Peter Burgard; Stefan Kölker Journal: Ann Neurol Date: 2010-11 Impact factor: 10.422
Authors: Mendel Tuchman; Brendan Lee; Uta Lichter-Konecki; Marshall L Summar; Marc Yudkoff; Stephen D Cederbaum; Douglas S Kerr; George A Diaz; Margaretta R Seashore; Hye-Seung Lee; Robert J McCarter; Jeffrey P Krischer; Mark L Batshaw Journal: Mol Genet Metab Date: 2008-06-17 Impact factor: 4.797
Authors: Georgianne L Arnold; Dwight D Koeberl; Dietrich Matern; Bruce Barshop; Nancy Braverman; Barbara Burton; Stephen Cederbaum; Annette Fiegenbaum; Cheryl Garganta; James Gibson; Stephen I Goodman; Cary Harding; Stephen Kahler; David Kronn; Nicola Longo Journal: Mol Genet Metab Date: 2007-12-21 Impact factor: 4.797
Authors: Georgianne L Arnold; Johan Van Hove; Debra Freedenberg; Arnold Strauss; Nicola Longo; Barbara Burton; Cheryl Garganta; Can Ficicioglu; Stephen Cederbaum; Cary Harding; Richard G Boles; Dietrich Matern; Pranesh Chakraborty; Annette Feigenbaum Journal: Mol Genet Metab Date: 2009-01-20 Impact factor: 4.797
Authors: Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson Journal: Genet Med Date: 2010-07 Impact factor: 8.822
Authors: Stefan Kölker; Ernst Christensen; James V Leonard; Cheryl R Greenberg; Avihu Boneh; Alberto B Burlina; Alessandro P Burlina; Marjorie Dixon; Marinus Duran; Angels García Cazorla; Stephen I Goodman; David M Koeller; Mårten Kyllerman; Chris Mühlhausen; Edith Müller; Jürgen G Okun; Bridget Wilcken; Georg F Hoffmann; Peter Burgard Journal: J Inherit Metab Dis Date: 2011-03-23 Impact factor: 4.982
Authors: Stefan Kölker; Dries Dobbelaere; Johannes Häberle; Peter Burgard; Florian Gleich; Marshall L Summar; Steven Hannigan; Samantha Parker; Anupam Chakrapani; Matthias R Baumgartner Journal: JIMD Rep Date: 2015-02-22